Tech Company Financing Transactions
Syros Pharmaceuticals Funding Round
Syros Pharmaceuticals closed a $40 million funding round on 1/13/2016. Backers included Deerfield Capital, Aisling Capital and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
1/13/2016
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance the Company's pipeline of gene control medicines, including a Phase 2 study of its lead program, SY-1425, which is expected to begin in the first half of 2016 in a genomically defined subset of patients with acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). The funds will also be used to further develop the Company's proprietary gene control platform with the aim of uncovering novel drug targets and biomarkers and developing medicines to treat cancer and other serious diseases.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
620 Memorial Dr. 300
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Syros Pharmaceuticals (Nasdaq: SYRS) is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nancy Simonian
Chief Financial Officer
Joseph Ferra
Chief Medical Officer
David Roth
Chief Scientific Officer
Eric Olson
VP - Bus. Development
Jeremy Springhorn
VP - General Counsel
Gerald Quirk
Browse more venture capital transactions:
Prev: 1/13/2016: Prevalent venture capital transaction
Next: 1/13/2016: GENEWIZ venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs